Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Bearish
5
Neutral
5
Bullish
4
Bearish
5
Neutral
13
Bullish
28
Bearish
0
Neutral
8
Bullish
24
Discovery themes featuring this stockDiscover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Nephrocare Health Services Limited (NephroPlus) operates Asia’s largest dialysis network, providing end‑to‑end dialysis care across formats (standalone clinics, captive hospital units, PPPs, home dialysis, dialysis on wheels) with 521 global clinics across India, Philippines, Uzbekistan, Nepal and KSA and over 36,000 guests served as of 9M FY26.
The company reported strong 9M FY26 results with revenue of ₹733.2 crore, adjusted EBITDA of ₹175.4 crore (23.9% margin) and adjusted PAT of ₹85.9 crore, reflecting a high operating leverage model enabled by scale, disciplined consumables procurement, and rapid international mix shift driving higher RPTs and ROCE expansion.
NephroPlus has a demonstrable international playbook: winning a large Uzbekistan PPP, establishing the world’s largest dialysis centre in Tashkent, becoming the third largest dialysis network in Philippines, and entering KSA via a JV, driving international revenue to 41% of 9M FY26 consolidated revenue and materially lifting blended realizations.
The business model is asset‑light and replicable with ~52% clinics under revenue‑sharing, strong hospital partnerships and a disciplined M&A integration engine; management targets 15%–20% revenue CAGR over the next 3–4 years, prioritizing ROCE‑accretive opportunities and cash conversion while selectively investing in new geographies and technology.
Healthcare Services
Healthcare Service Provider
7,133 Cr
Low Risk
92.8
58.9
2.0
6.4
767.95
445.00
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stock
Nephrocare Health Services Ltd (NEPHROPLUS) is currently trading at 746.10 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Nephrocare Health Services Limited (NephroPlus) operates Asia’s largest dialysis network, providing end‑to‑end dialysis care across formats (standalone clinics, captive hospital units, PPPs, home dialysis, dialysis on wheels) with 521 global clinics across India, Philippines, Uzbekistan, Nepal and KSA and over 36,000 guests served as of 9M FY26. The company reported strong 9M FY26 results with revenue of ₹733.2 crore, adjusted EBITDA of ₹175.4 crore (23.9% margin) and adjusted PAT of ₹85.9 crore, reflecting a high operating leverage model enabled by scale, disciplined consumables procurement, and rapid international mix shift driving higher RPTs and ROCE expansion. NephroPlus has a demonstrable international playbook: winning a large Uzbekistan PPP, establishing the world’s largest dialysis centre in Tashkent, becoming the third largest dialysis network in Philippines, and entering KSA via a JV, driving international revenue to 41% of 9M FY26 consolidated revenue and materially lifting blended realizations. The business model is asset‑light and replicable with ~52% clinics under revenue‑sharing, strong hospital partnerships and a disciplined M&A integration engine; management targets 15%–20% revenue CAGR over the next 3–4 years, prioritizing ROCE‑accretive opportunities and cash conversion while selectively investing in new geographies and technology.
Over the past 52 weeks, Nephrocare Health Services Ltd has traded between a low of ₹445.00 and a high of ₹767.95. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Nephrocare Health Services Ltd has a market capitalization of approximately 7,132.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Nephrocare Health Services Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 92.83 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 7,132.72 Cr, Nephrocare Health Services Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Nephrocare Health Services Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Nephrocare Health Services Ltd is 92.83. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
535.45 | 10,894 Cr | 57.33 | 7.20 | 0.95 | 12.56 | 16.25 | 8.94 | ||
533.00 | 8,526 Cr | 52.29 | 16.63 | 2.61 | 27.85 | 33.90 | 21.79 | ||
746.10 | 7,133 Cr | 92.83 | 6.39 | 0.00 | 6.88 | 13.18 | 5.22 | ||
536.00 | 1,749 Cr | 17.24 | 1.78 | 0.37 | 10.35 | 10.42 | 5.56 | ||
270.10 | 1,395 Cr | 43.33 | 5.70 | 0.19 | 13.15 | 14.38 | 7.01 | ||
695.65 | 1,300 Cr | 18.72 | 9.21 | 0.00 | 49.21 | 65.70 | 27.21 | ||
1257.00 | 1,101 Cr | 18.79 | 3.39 | 0.39 | 18.06 | 23.58 | 15.85 | ||
| Median: 7 Co. | — | 536.00 | 1,749 Cr | 43.33 | 6.39 | 0.37 | 13.15 | 16.25 | 8.94 |
